ArticleBMC medical imaging2025
Temporal evolution of MRI findings and survival outcomes in patients with brain metastases after stereotactic radiosurgery.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Volumetric analysis of radiographic changes after stereotactic radiosurgery for treatment of non-responding brain metastases.Journal of neuro-oncology · 2026Article
- Post-therapy imaging of adult brain tumours: patterns, pitfalls, and practical framework.Insights into imaging · 2026Article
- Imaging Changes and Clinical Outcome after MR-Guided Laser Interstitial Thermal Therapy.Stereotactic and functional neurosurgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to investigate the temporal evolution of magnetic resonance imaging (MRI) findings in brain metastases following stereotactic radiosurgery (SRS) and their correlation with treatment response and survival outcomes. By analyzing volumetric changes in tumor size, perilesional edema, and necrotic components, we seek to identify imaging biomarkers that predict prognosis and treatment efficacy.
methodsA retrospective analysis was conducted on 97 patients (200 metastatic lesions) who underwent SRS for brain metastases between 2010 and 2022. Multiparametric MRI (MPMRI) scans were analyzed at four distinct follow-up periods: 1 to 3 months, 3 to 8 months, 8 to 16 months, and 16 to 24 months post-SRS. Volumetric measurements of tumor size, perilesional edema, and necrosis were obtained using semi-automated segmentation. Apparent diffusion coefficient (ADC) values and relative cerebral blood volume (rCBV) ratios were also assessed. Statistical analyses, including Kaplan-Meier survival curves and ROC analysis, were performed to determine prognostic imaging biomarkers.
resultsThe most significant reduction in tumor and perilesional edema volume occurred within the first 1 to 3 months post-SRS and continued until the 8th month. A transient increase in lesion size (pseudoprogression) was observed in 31.5% of cases, predominantly between 3 and 8 months post-SRS. Pretreatment tumor volume was found to be significantly associated with treatment response. ROC analysis identified 1.22 cm³ as the optimal cutoff value for differentiating between Group A (good response) and Group B (poor response) lesions (AUC = 0.754, sensitivity = 87.0%, specificity = 57.1%). Survival analysis revealed that higher pretreatment tumor volume, larger necrotic volume, and extensive perilesional edema were associated with shorter survival times (p < 0.05). No significant association was found between survival and ADC or rCBV.
conclusionFollowing SRS, early reductions in tumor and edema volume were observed, while 31.5% of cases showed transient enlargement. Smaller tumors responded better to SRS, whereas larger volume, extensive edema, and necrosis were linked to shorter survival. Given the high rate of pseudoprogression, not every post-treatment size increase indicates true progression. A wait-and-see approach may help avoid unnecessary interventions in selected cases. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.